Cardinal Health signs letter to extend CVS deal to 2032
The reaffirmed fiscal 2027 non-GAAP EPS range is $12.40 to $12.60, with long-term growth guidance of 12% to 14%.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Cardinal Health (CAH) entered into a binding letter of intent with CVS Health to extend its pharmaceutical distribution agreements through June 30, 2032. The extension continues Cardinal Health’s current scope of distribution services.
Cardinal Health reaffirmed previously issued fiscal 2027 non-GAAP EPS guidance of $12.40 to $12.60. The company described this range as 13% to 15% growth based on adjusted fiscal 2026 results that exclude the fiscal 2026 benefit from an IEEPA tariff refund. It also reaffirmed long-term non-GAAP EPS growth guidance of 12% to 14%. Cardinal Health said further updates may be provided during its first-quarter earnings call on November 5, 2026.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Distribution agreement term: Through June 30, 2032
Fiscal 2027 non-GAAP EPS guidance: $12.40 to $12.60
Fiscal 2027 non-GAAP EPS growth guidance: 13% to 15%
+2 more
5 metrics
Distribution agreement term
Through June 30, 2032
Extension with CVS Health
Fiscal 2027 non-GAAP EPS guidance
$12.40 to $12.60
Reaffirmed guidance
Fiscal 2027 non-GAAP EPS growth guidance
13% to 15%
Based on adjusted fiscal 2026 results, excluding the fiscal 2026 benefit from an IEEPA tariff refund
Long-term non-GAAP EPS growth guidance
12% to 14%
Reaffirmed guidance
First-quarter earnings call
November 5, 2026
Further updates may be provided
Key Terms
Letter of Intent, non-GAAP EPS, IEEPA tariff refund
3 terms
Letter of Intent technical
"entered into a binding Letter of Intent to extend its existing distribution agreement"
A letter of intent is a document that shows an agreement in principle between parties to work towards a future deal or transaction. It outlines their intentions and key terms, acting like a roadmap before a formal contract is signed. For investors, it signals serious interest and helps clarify expectations early in the process.
non-GAAP EPS financial
"fiscal year 2027 non-GAAP EPS guidance"
Non-GAAP EPS is a measure of a company's profit per share that excludes certain expenses or income items that are included in standard accounting reports. It is used by investors to get a clearer picture of the company's core performance, much like removing one-time costs from a personal budget to see regular spending habits. This adjusted figure helps investors compare companies more consistently and understand their ongoing profitability.
IEEPA tariff refund regulatory
"exclude the fiscal year 2026 benefit from IEEPA tariff refund"
A IEEPA tariff refund is the repayment of customs duties or import tariffs that were originally charged under trade measures enacted using the International Emergency Economic Powers Act (IEEPA). It matters to investors because getting a refund is like reclaiming a past expense: it can increase a company’s cash or reduce its reported cost of goods, and may signal changing government trade policy or successful legal or administrative challenges to the tariffs.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What agreement is Cardinal Health (CAH) extending with CVS Health?
Cardinal Health entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032. The extension continues Cardinal Health’s current scope of distribution services.
What is Cardinal Health’s (CAH) fiscal 2027 EPS guidance?
Cardinal Health reaffirmed fiscal 2027 non-GAAP EPS guidance of $12.40 to $12.60, described as 13% to 15% growth based on adjusted fiscal 2026 results that exclude the fiscal 2026 benefit from an IEEPA tariff refund.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 1, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | |||||||||||||||||||||||||||
(614 ) 757-5000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. p
Item 7.01: Regulation FD Disclosure
On October 1, 2026, Cardinal Health, Inc. (the “Company”) issued a news release announcing that it had entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. In connection with this announcement, the Company also reaffirmed its previously issued fiscal year 2027 non-GAAP earnings per share (EPS) guidance range of $12.40 to $12.60 and its long-term non-GAAP EPS growth range guidance of 12% to 14%. A copy of the news release is included as Exhibit 99.1 to this report.
Item 9.01: Financial Statements and Exhibits
(d) Exhibits
| Exhibit Number | Exhibit Description | ||||
| 99.1 | News release issued by the Company on October 1, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cardinal Health, Inc. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | October 1, 2026 | By: | /s/ AARON E. ALT | |||||||||||
| Aaron E. Alt | ||||||||||||||
| Chief Financial Officer | ||||||||||||||
3
Exhibit 99.1
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
DUBLIN, Ohio, October 1, 2026 – Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, reflecting the continuation of Cardinal Health's current scope of distribution services.
“We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers," stated Jason Hollar, CEO of Cardinal Health.
In connection with the renewal, Cardinal Health has reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth1 ($12.40 to $12.60) and its long-term non-GAAP EPS growth rate guidance of 12% to 14%. Further updates may be provided during the company’s upcoming first quarter earnings call on November 5, 2026.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company’s customer-centric focus drives continuous improvement and leads to innovative solutions that improve people’s lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company’s customer-centric focus drives continuous improvement and leads to innovative solutions that improve people’s lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.
Contacts
Media: Erich Timmerman, erich.timmerman@cardinalhealth.com and 614.757.8231
Investors: David Frost, david.frost@cardinalhealth.com and 614.757.7852
1 Growth rates for fiscal year 2027 guidance based upon adjusted fiscal year 2026 results which exclude the fiscal year 2026 benefit from IEEPA tariff refund.